AUS
NZ
UK
CA
USA
IND
Healthcare
Recce Pharmaceuticals Ltd Weakens as All Ordinaries Healthcare Volatility Rises
March 06, 2026 03:50 PM AEDT| By SamRecce Pharmaceuticals Ltd declines despite revenue expansion, reflecting widened losses and shifting sentiment within the All Ordinaries healthcare segment.
PYC Therapeutics Update Sparks ASX Market Interest
March 06, 2026 11:25 AM AEDT| By SamHighlights,PYC Therapeutics expands its quoted share base on the Australian market,Additional securities may influence liquidity and trading participation,Development-focused biotechnology activity continues to attract attention,PYC Therapeutics expa...
Rhythm Biosciences Share Update Draws Attention Across ASX Market
March 06, 2026 11:12 AM AEDT| By SamRhythm Biosciences progresses quotation of additional ordinary shares, illustrating capital market engagement and the evolving role of biotechnology firms within Australia’s healthcare innovation ecosystem.
ASX 200 Spotlight: Telix Drives Cancer AI Push
March 06, 2026 01:24 AM AEDT| By SamHighlights,Telix expands precision oncology pipeline across major cancers,AI integration reshapes radiopharmaceutical discovery strategy,Global commercial rollout strengthens Australian biotech presence,Telix Pharmaceuticals Limited (ASX:TLX) is an A...
Mesoblast ASX 100 Index Outlook After Earnings Update
March 03, 2026 05:29 PM AEDT| By SamHighlights,Mesoblast’s earnings update sharpens market focus on valuation outlook.,Ryoncil regulatory progress drives renewed sector attention.,Biotech sentiment shifts across the broader Australian share market.,Australia’s biotechnology landscape c...
ASX 200 Watch: High Volume Shakes Incannex Healthcare
March 03, 2026 11:12 AM AEDT| By SamA surge in trading activity around a clinical-stage healthcare company highlights how liquidity, sentiment and sector dynamics interact within Australia’s evolving biotechnology landscape.
CSL Share Price Reaction Draws Attention on ASX
March 02, 2026 07:15 PM AEDT| By SamCSL Limited share performance on the ASX gains attention as buyback activity continues and dividend timelines approach. Market sentiment also reflects broader trends across Australia’s healthcare and defensive sectors.
Neuren Pharma Update: Buy-Back Plan And Pipeline Focus
March 02, 2026 06:43 PM AEDT| By SamNeuren Pharmaceuticals outlines earnings update, share buy-back plan and pipeline progress, highlighting royalty momentum and clinical development focus while shaping investor sentiment around the company’s neurological disorder research strategy.
CT:VQ Approval Puts 4DMedical’s US Opportunity in Focus
February 28, 2026 09:08 AM AEDT| By Sam4DMedical’s CT:VQ approval in the U.S. highlights the company’s focus on advanced lung imaging technology, expanding healthcare adoption and strengthening its commercial strategy in the evolving global medical imaging market.
CSL Share Price in Spotlight After Lilly Deal
February 27, 2026 08:23 PM AEDT| By SamCSL’s licensing agreement and earnings update have shifted investor focus toward valuation, margin recovery and long-term growth drivers within Australia’s healthcare sector.
Could (ASX:CUV) Be the Next Big ASX Comeback?
February 27, 2026 06:56 PM AEDT| By SamClinuvel Pharmaceuticals Ltd (ASX:CUV) combines a resilient rare-disease franchise with expanding dermatology programs, positioning the biotech player at a critical stage of growth within Australia’s equity market.
ASX 200 Spotlight: Avecho’s Governance Filing Strengthens Market Transparency
February 27, 2026 05:20 PM AEDT| By SamAvecho filed updated corporate governance documentation with the ASX, reinforcing structured disclosure, regulatory compliance, and transparency within the Australian healthcare sector.
Healthcare Giants Reveal Earnings Divide
February 27, 2026 04:58 PM AEDT| By SamA comprehensive look at how leading Australian healthcare companies are navigating earnings recovery, integration strategy and commercial biotech expansion within the broader market landscape.
ASX Market Signals: What 4DMedical’s Share Move Means for Traders
February 27, 2026 04:06 PM AEDT| By SamThis article explores how 4DMedical’s capital move highlights evolving market positioning, healthcare innovation, and broader structural changes shaping Australia’s dynamic financial ecosystem.
Telix Pharmaceuticals Strengthens Oncology Pipeline Within ASX 200
February 27, 2026 03:01 PM AEDT| By SamTelix Pharmaceuticals expands its radiopharmaceutical portfolio, combining commercial imaging revenue with an advancing oncology therapy pipeline.
How a Smart Funding Path Is Reshaping Innovation on the ASX Stock Market
February 27, 2026 12:02 PM AEDT| By SamFlexible funding models and research incentives are reshaping how healthcare innovators plan, develop, and sustain long-term scientific progress on the Australian share market.
Global Obesity Drug Race Sends Signals to the ASX Market
February 27, 2026 11:48 AM AEDT| By SamGlobal obesity drug innovation is intensifying, with delivery design and clinical confidence shaping leadership, while Australian healthcare markets continue to track these international signals closely.
Is IMU Drawing Fresh Attention in the All Ordinaries Ahead of Key US Data Reveal?
February 27, 2026 11:42 AM AEDT| By SamImugene will present Azer-Cel clinical data at a major US healthcare conference, reinforcing biotechnology visibility within the All Ordinaries index.
ASX Market Update: Is Lumos Building Momentum in the ASX All Ords Healthcare Segment?
February 27, 2026 11:42 AM AEDT| By SamLumos improved operating cash flow on FebriDx momentum while reporting a wider first-half loss within the ASX All Ords healthcare segment.
Anteris Advances Clinical Program Within the All Ordinaries Healthcare Segment
February 27, 2026 11:34 AM AEDT| By SamAnteris reports operating cash outflow as the Paradigm clinical trial advances, highlighting structural heart innovation within the All Ordinaries healthcare sector.
Advertise your brand on Kalkine Media